Trial Profile

A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator's Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 05 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Panitumumab (Primary) ; Sotorasib (Primary) ; Regorafenib; Tipiracil/trifluridine
Indications Adenocarcinoma; Colorectal cancer
Focus Registrational; Therapeutic Use
Acronyms CodeBreak300
Sponsors Amgen

27 Apr 2026 Status changed from active, no longer recruiting to completed.
06 Feb 2026 Planned End Date changed from 31 Jan 2026 to 14 May 2026.
30 Apr 2025 Results (n=140) assessing the baseline genetic co-occurring alterations and their impact on the efficacy of sotorasib plus panitumumab in this study, presented at the 116th Annual Meeting of the American Association for Cancer Research.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com